These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11321183)

  • 1. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068.
    Mildvan D; Bassiakos Y; Zucker ML; Hyslop N; Krown SE; Sacks HS; Zachary J; Paredes J; Fessel WJ; Rhame F; Kramer F; Fischl MA; Poiesz B; Wood K; Ruprecht RM; Kim J; Grossberg SE; Kasdan P; Bergé P; Marshak A; Pettinelli C
    Antivir Ther; 1996 Apr; 1(2):77-88. PubMed ID: 11321183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection.
    Frissen PH; Brinkman K; Ten Napel CH; van der Ende IM; van Buuren IA; Boucher CA; Reiss P; Lange JM
    Antivir Ther; 1996 Apr; 1(2):89-97. PubMed ID: 11321184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label phase I study of combination therapy with zidovudine and interferon-beta in patients with AIDS-related Kaposi's sarcoma: AIDS Clinical Trials Group Protocol 057.
    Miles S; Levine A; Feldstein M; Carden J; Cabriallas S; Marcus S; Mitsuyasu R; Gill P
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):17-23. PubMed ID: 9557213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Cheeseman SH; Havlir D; McLaughlin MM; Greenough TC; Sullivan JL; Hall D; Hattox SE; Spector SA; Stein DS; Myers M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):141-51. PubMed ID: 7530585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
    Krown SE; Aeppli D; Balfour HH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
    Meng TC; Fischl MA; Cheeseman SH; Spector SA; Resnick L; Boota A; Petrakis T; Wright B; Richman DD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):152-60. PubMed ID: 7834398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
    McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
    Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of interferon alpha therapy for HIV type 1 infection.
    Haas DW; Lavelle J; Nadler JP; Greenberg SB; Frame P; Mustafa N; St Clair M; McKinnis R; Dix L; Elkins M; Rooney J
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):183-90. PubMed ID: 10710206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
    Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
    Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
    Sangkitporn S; Shide L; Klinbuayaem V; Leenasirimakul P; Wirayutwatthana NA; Leechanachai P; Dettrairat S; Kunachiwa W; Thamlikitkul V
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):704-8. PubMed ID: 16124442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
    Rezza G; Galai N; Pezzotti P; Vlahov D; Graham NM; Viale P; Angarano G
    Antivir Ther; 1997 Jul; 2(3):167-74. PubMed ID: 11322271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.